Inj, vutrisiran, 1 mg
Products billed under this code include Amvuttra.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Amvuttra.
Payment limit per 1 MG, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Amvuttra | Alnylam Pharmaceuticals, Inc. | 71336-1003-01 | 25 | $125,223.475 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5,008.939 | −$3.66 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $5,012.599 | −$6.674 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $5,019.273 | +$9.715 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $5,009.558 | +$5.919 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $5,003.639 | +$19.784 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $4,983.855 | +$27.545 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $4,956.31 | +$38.561 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $4,917.749 | −$8.253 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $4,926.002 | −$6.107 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $4,932.109 | −$3.105 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $4,935.214 | −$12.169 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $4,947.383 | −$2.991 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $4,950.374 | +$9.424 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $4,940.95 | +$65.096 | 1 MG | Inj, vutrisiran, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $4,875.854 | – | 1 MG | Inj, vutrisiran, 1 mg | v1, posted February 23, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.